EVALUATING NON-AIDS INFECTIOUS DISEASE CONTROL MEASURES

评估非艾滋病传染病控制措施

• 批准号: 2296300
• 负责人: Gilbert M. Schiff
• 金额: $ 165.92万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2296300
• 关键词: EVALUATING; NON; AIDS; INFECTIOUS; DISEASE

The overall objective of this contract is to evaluate control measures for infectious diseases other than AIDS. There are still many infectious diseases for which effective and highly safe vaccines and therapies have yet to be developed. Additionally, for some diseases improved vaccines are needed that will prevent infection and disease in age groups not currently protected and that will offer increased safety. New vaccine and drug candidates continue to be developed, spurred on by advances in the basic sciences. The capacity to evaluate these new and improved vaccine and therapy candidates in an efficient and expeditious manner is an essential element of the efforts of the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). This contract for a Vaccine and Treatment Evaluation Unit [VTEU] is an integral part of these efforts and supports Phase I and Phase II clinical trials of bacterial and viral vaccines, other biologicals, and drugs as preventative and therapeutic measures against infectious diseases in people of all ages and risk categories. In selected circumstances, Phase III vaccine trials may also be undertaken. Also of importance is the epidemiologic surveillance of pathogens that are of special interest to NIAID, and capacity to undertake limited, relevant, basic and preclinical research directly linked to vaccine biology and immunology.

该合同的总体目的是评估控制措施 除艾滋病以外的其他传染病。 仍然有很多感染力 有效且高度安全的疫苗和疗法的疾病 尚未开发。 此外，对于某些疾病，改善的疫苗是 需要的需要防止年龄段的感染和疾病 受到保护，这将提供更高的安全性。 新疫苗和药物 候选人继续开发，受到基本进步的刺激 科学。 评估这些新的和改进的疫苗的能力以及 以有效而迅速的方式候选治疗是必不可少的 微生物学和感染力的努力的要素 国家过敏和感染研究所的疾病（DMID） 疾病（NIAID）。 该疫苗和治疗评估的合同 [VTEU]单位是这些努力的组成部分，并支持第一阶段和 细菌和病毒疫苗的II期临床试验，其他 生物学和药物作为预防和治疗措施 各个年龄段和风险类别的人的传染病。 在选定中 情况，也可以进行III期疫苗试验。 也是 重要性是对病原体的流行病学监测 NIAID的特殊兴趣，以及具有有限，相关性的能力 与疫苗生物学直接相关的基础和临床前研究 免疫学。